Company intelligence / Profile preview

Bone Care International

Madison, Wisconsin, USA

Ownership: Private
Development stage: Other

Overview

Bone Care International was a specialty pharmaceutical company focused on the development and commercialization of novel therapeutic products for the treatment of nephrology, oncology, and dermatology. The company's primary focus was on its proprietary pro-vitamin D hormone technology, specifically its lead product Hectorol (doxercalciferol). Hectorol was approved for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and those with Stage 3 or 4 CKD. The company was acquired by Genzyme Corporation in 2005 for approximately $600 million to bolster Genzyme's renal portfolio.

Therapeutic areas: EndocrinologyNephrologyDermatology
Modalities: Small moleculeHormone
Industry: Biotech

Partnerships

Medice

Beyond the preview

Go deeper on Bone Care International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bone Care International.

Explore the full profile